Penumbra, Inc. - PEN STOCK NEWS

Penumbra, Inc. (NYSE: PEN) has launched the Lightning Flash™, a cutting-edge mechanical thrombectomy system, following FDA clearance. This system features innovative Lightning Intelligent Aspiration technology with dual clot detection, enhancing the efficiency of removing blood clots in venous and pulmonary areas. The device employs advanced catheter design, promising improved patient outcomes and safety. Lightning Flash is part of Penumbra's Indigo System and aims to transform the standard of care in thrombectomy, benefiting a broad spectrum of patients.

Penumbra, Inc. (NYSE: PEN) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 1:30 PM ET. The conference is a key event in the healthcare sector, gathering influential industry leaders and investors.

A webcast of the presentation will be accessible on the company's website for two weeks post-event. Based in Alameda, California, Penumbra is known for its innovative therapies addressing critical healthcare needs globally.

Penumbra, Inc. (NYSE: PEN) has unveiled the REAL y-Series™, the first hands-free, non-tethered virtual reality rehabilitation platform. This innovative product addresses both upper and lower extremities using sensors that allow real-time tracking of full body movement. Designed to enhance patient engagement, its customizable exercises can support over 50 million rehabilitation patients in the U.S. The demand for advanced rehabilitation solutions is underscored by a recent survey revealing that nearly 75% of physical therapists cite patient compliance as a major challenge, while 65% are eager to use VR technologies.

Penumbras, Inc. (NYSE: PEN) announced a 12.4% increase in third-quarter revenue, totaling $213.7 million, compared to $190.1 million in Q3 2021. Revenue from vascular products rose by 17.0% to $123.4 million, while neuro product sales increased by 6.7% to $90.3 million. Gross profit was $135.3 million with a gross margin of 63.3%. The company updated its 2022 revenue guidance to $840-$845 million, reflecting 12-13% growth. Despite strong performance, the Lightning Flash product launch is delayed to Q1 2023, impacting short-term revenue expectations.

Penumbra, Inc. (NYSE: PEN) will present at the Jefferies London Healthcare Conference on November 15, 2022, at 9:10 AM GMT / 1:10 AM PT. The presentation will be accessible via an audio webcast on their website for at least two weeks following the event. This healthcare company focuses on innovative therapies and supports providers in over 100 countries. For more details, visit www.penumbrainc.com.

Penumbra, Inc. (NYSE: PEN) has scheduled a conference call on November 3, 2022, at 4:30 PM ET to discuss its third quarter 2022 financial results. The earnings release will be made available after market close on the same day. Interested parties can access the call by dialing (888) 330-2443 or via the webcast on the company's website. Penumbra focuses on innovative therapies and has a significant presence in over 100 countries, supporting healthcare providers with its broad product portfolio.

Penumbra, Inc. (NYSE: PEN) has announced a collaboration with Asahi Intecc Co. to introduce the Indigo™ Aspiration System in Japan after gaining regulatory approval. This advanced peripheral mechanical thrombectomy technology targets blood clot removal in arterial and venous systems, addressing conditions like acute limb ischemia and pulmonary embolism. The system features cutting-edge Lightning technology, designed to differentiate between clot and blood, minimizing blood loss during procedures. This partnership aims to enhance patient care and meet the increasing medical needs in Japan.

Penumbra, Inc. (NYSE: PEN) announced the European launch of its RED® Reperfusion Catheters following CE Mark approval. These catheters, part of the Penumbra System®, are designed for mechanical thrombectomy in acute ischemic stroke patients. Initial data from the INSIGHT Registry revealed a 68.9% first-pass revascularization success rate across all clot types. The RED catheters feature advanced trackability and aspiration technologies, enhancing their effectiveness. This expansion aims to improve treatment options for stroke patients in Europe, enabling faster and more efficient clot removal.

Penumbra, Inc. (NYSE: PEN) announced promising results from its initial INSIGHT Registry data, revealing that its RED^® reperfusion catheters achieved a first-pass revascularization rate of 68.9% in acute ischemic stroke patients. Additionally, findings from the COMPLETE study indicate that the Penumbra System effectively treats patients with tandem lesions and those in the late treatment window, with successful revascularization rates of 89% for tandem lesions and 83.2% for late window patients. These data were presented at the 2022 WFITN conference in Kyoto, Japan.